|
1
|
Boffa MB and Koschinsky ML: Lipoprotein(a)
and cardiovascular disease. Biochem J. 481:1277–1296. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lusis AJ: Atherosclerosis. Nature.
407:233–241. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hassan HA, Ahmed HS and Hassan DF: Free
radicals and oxidative stress: Mechanisms and therapeutic targets.
Hum Antibodies. 32:151–167. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aleksandrowicz M, Konop M, Rybka M,
Mazurek Ł, Stradczuk-Mazurek M, Kciuk M, Bądzyńska B, Dobrowolski L
and Kuczeriszka M: Dysfunction of microcirculation in
atherosclerosis: Implications of nitric oxide, oxidative stress,
and inflammation. Int J Mol Sci. 26:64672025. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Batty M, Bennett MR and Yu E: The role of
oxidative stress in atherosclerosis. Cells. 11:38432022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jakubowski H and Witucki Ł: Homocysteine
metabolites, endothelial dysfunction, and cardiovascular disease.
Int J Mol Sci. 26:7462025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu L, Liao Y and Jiang B: Role of ROS and
autophagy in the pathological process of atherosclerosis. J Physiol
Biochem. 80:743–756. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Howden R: Nrf2 and cardiovascular defense.
Oxid Med Cell Longev. 2013:1043082013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jomova K, Raptova R, Alomar SY, Alwasel
SH, Nepovimova E, Kuca K and Valko M: Reactive oxygen species,
toxicity, oxidative stress, and antioxidants: Chronic diseases and
aging. Arch Toxicol. 97:2499–2574. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mimura J and Itoh K: Role of Nrf2 in the
pathogenesis of atherosclerosis. Free radical biology &
medicine. 88:221–232. 2015. View Article : Google Scholar
|
|
11
|
O'Rourke SA, Shanley LC and Dunne A: The
Nrf2-HO-1 system and inflammaging. Front Immunol. 15:14570102024.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grebe A, Hoss F and Latz E: NLRP3
Inflammasome and the IL-1 pathway in atherosclerosis. Circ Res.
122:1722–1740. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang K, Liu H, Sun W, Guo J, Jiang Z, Xu S
and Miao Z: Eucalyptol alleviates avermectin exposure-induced
apoptosis and necroptosis of grass carp hepatocytes by regulating
ROS/NLRP3 axis. Aquat Toxicol. 264:1067392023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fu J and Wu H: Structural mechanisms of
NLRP3 inflammasome assembly and activation. Annu Rev Immunol.
41:301–316. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tall AR and Bornfeldt KE: Inflammasomes
and atherosclerosis: A mixed picture. Circ Res. 132:1505–1520.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hort J, Duning T and Hoerr R: Ginkgo
biloba Extract EGb 761 in the treatment of patients with mild
neurocognitive impairment: A systematic review. Neuropsychiatr Dis
Treat. 19:647–660. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Boateng ID: Ginkgols and bilobols in
Ginkgo biloba L. A review of their extraction and bioactivities.
Phytother Res. 37:3211–3223. 2023. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang R, Han D, Li Z, Shen C, Zhang Y, Li
J, Yan G, Li S, Hu B, Li J and Liu P: Corrigendum: Ginkgolide C
alleviates myocardial ischemia/reperfusion-induced inflammatory
injury via inhibition of CD40-NF-κB pathway. Front Pharmacol.
15:14925202024. View Article : Google Scholar
|
|
19
|
Li B, Zhang B, Li Z, Li S, Li J, Wang A,
Hou J, Xu J and Zhang R: Ginkgolide C attenuates cerebral
ischemia/reperfusion-induced inflammatory impairments by
suppressing CD40/NF-κB pathway. J Ethnopharmacol. 312:1165372023.
View Article : Google Scholar
|
|
20
|
Emanueli C, Schmidt AM and Golledge J:
Unveiling intriguing links between limb ischemia, systemic
inflammation, and progressive atherosclerosis: A tangled and
interconnected web. Arterioscler Thromb Vasc Biol. 43:907–909.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tasouli-Drakou V, Ogurek I, Shaikh T,
Ringor M, DiCaro MV and Lei K: Atherosclerosis: A comprehensive
review of molecular factors and mechanisms. Int J Mol Sci.
26:13642025. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang X, Shen Y, Shang M, Liu X and Munn
LL: Endothelial mechanobiology in atherosclerosis. Cardiovasc Res.
119:1656–1675. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang DR, Wang MY, Zhang CL and Wang Y:
Endothelial dysfunction in vascular complications of diabetes: A
comprehensive review of mechanisms and implications. Front
Endocrinol (Lausanne). 15:13592552024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He B, Nie Q, Wang F, Wang X, Zhou Y, Wang
C, Guo J, Fan X, Ye Z, Liu P and Wen J: Hyperuricemia promotes the
progression of atherosclerosis by activating endothelial cell
pyroptosis via the ROS/NLRP3 pathway. J Cell Physiol.
238:1808–1822. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang B, Yu J, Bao L, Feng D, Qin Y, Fan
D, Hong X and Chen Y: Cynarin inhibits microglia-induced pyroptosis
and neuroinflammation via Nrf2/ROS/NLRP3 axis after spinal cord
injury. Inflamm Res. 73:1981–1994. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin J, Sun X and Yang L: Effects and
safety of Ginkgo biloba on depression: A systematic review and
meta-analysis. Front Pharmacol. 15:13640302024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fang WH, Bonavida V, Agrawal DK and
Thankam FG: Hyperlipidemia in tendon injury: Chronicles of
low-density lipoproteins. Cell Tissue Res. 392:431–442. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Silva H and Martins FG: Cardiovascular
activity of Ginkgo biloba-An insight from healthy subjects. Biology
(Basel). 12:152022.
|
|
29
|
Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ
and Han M: Inflammation and atherosclerosis: Signaling pathways and
therapeutic intervention. Signal Transduct Target Ther. 7:1312022.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weber C, Habenicht AJR and von
Hundelshausen P: Novel mechanisms and therapeutic targets in
atherosclerosis: Inflammation and beyond. Eur Heart J.
44:2672–2681. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang S, Hong F, Ma C and Yang S: Hepatic
lipid metabolism disorder and atherosclerosis. Endocr Metab Immune
Disord Drug Targets. 22:590–600. 2022. View Article : Google Scholar
|
|
32
|
Lubrano V, Ndreu R and Balzan S: Classes
of lipid mediators and their effects on vascular inflammation in
atherosclerosis. Int J Mol Sci. 24:16372023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bu LL, Yuan HH, Xie LL, Guo MH, Liao DF
and Zheng XL: New dawn for atherosclerosis: Vascular endothelial
cell senescence and death. Int J Mol Sci. 24:151602023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pintó X, Fanlo M, Esteve V and Millán J:
Remnant cholesterol, vascular risk, and prevention of
atherosclerosis. Clin Investig Arterioscler. 35:206–217.
2023.PubMed/NCBI
|
|
35
|
Gaggini M, Gorini F and Vassalle C: Lipids
in atherosclerosis: Pathophysiology and the role of calculated
lipid indices in assessing cardiovascular risk in patients with
hyperlipidemia. Int J Mol Sci. 24:752022. View Article : Google Scholar
|
|
36
|
Dabravolski SA, Churov AV, Beloyartsev DF,
Kovyanova TI, Lyapina IN, Sukhorukov VN and Orekhov AN: The role of
NRF2 function and regulation in atherosclerosis: An update. Mol
Cell Biochem. 480:3935–3949. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jomova K, Alomar SY, Valko R, Liska J,
Nepovimova E, Kuca K and Valko M: Flavonoids and their role in
oxidative stress, inflammation, and human diseases. Chem Biol
Interact. 413:1114892025. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yan Q, Liu S, Sun Y, Chen C, Yang S, Lin
M, Long J, Yao J, Lin Y, Yi F, et al: Targeting oxidative stress as
a preventive and therapeutic approach for cardiovascular disease. J
Transl Med. 21:5192023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang Z, Dai Y, Xiao Y and Liu Q:
Protective effects of catalpol on cardio-cerebrovascular diseases:
A comprehensive review. J Pharm Anal. 13:1089–1101. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Han H, Zhang G, Zhang X and Zhao Q:
Nrf2-mediated ferroptosis inhibition: A novel approach for managing
inflammatory diseases. Inflammopharmacology. 32:2961–2986. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Meng T, Li X, Li C, Liu J, Chang H, Jiang
N, Li J, Zhou Y and Liu Z: Natural products of traditional Chinese
medicine treat atherosclerosis by regulating inflammatory and
oxidative stress pathways. Front Pharmacol. 13:9975982022.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Huang Z, Wu M, Zeng L and Wang D: The
beneficial role of Nrf2 in the endothelial dysfunction of
atherosclerosis. Cardiol Res Pract. 2022:42877112022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pfefferlé M and Vallelian F: Transcription
factor NRF2 in shaping myeloid cell differentiation and function.
Adv Exp Med Biol. 1459:159–195. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang XN, Yu ZL, Chen JY, Li XY, Wang ZP,
Wu M and Liu LT: The crosstalk between NLRP3 inflammasome and gut
microbiome in atherosclerosis. Pharmacol Res. 181:1062892022.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tanase DM, Valasciuc E, Gosav EM, Ouatu A,
Buliga-Finis ON, Floria M, Maranduca MA and Serban IL: Portrayal of
NLRP3 inflammasome in atherosclerosis: Current knowledge and
therapeutic targets. Int J Mol Sci. 24:81622023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang H and Dhalla NS: The role of
Pro-inflammatory cytokines in the pathogenesis of cardiovascular
disease. Int J Mol Sci. 25:10822024. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Asemi R, Omidi Najafabadi E, Mahmoudian Z,
Reiter RJ, Mansournia MA and Asemi Z: Melatonin as a treatment for
atherosclerosis: Focus on programmed cell death, inflammation and
oxidative stress. J Cardiothorac Surg. 20:1942025. View Article : Google Scholar : PubMed/NCBI
|
